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Proteomics is quite mature to assimilate new market
niches. These niches are created by natural curiosity of
proteome scientists, challenged by a number of difﬁculties
in developing actual deliverables for the market over 20
years of hard and enthusiastic work. Playing the proteomics
challenge without a team may be ﬁnancially risky. We have
launched new Flagship Programs of EuPA Initiatives in order
to help ﬁll the gap between the large and heterogeneous
European scientiﬁc community and the world of enterprises.
During the session we will discuss how the social networking
environment could be used to keep pace of investments in
proteomics. Representatives of future and current start-ups,
SMEs and large established corporations are invited for this
brainstorming.
http://dx.doi.org/10.1016/j.euprot.2015.07.002
Standardization initiative. Integrating
proteomic strengths across Europe
Fernando J. Corrales
Center for Applied Medical Investigation,
University of Navarra, Spain
Mass spectrometry has experienced huge advances in the
last decade increasing the accuracy and capacity of pro-
tein/peptide measurements in complex biological samples.
The possibility of massive protein identiﬁcation and quan-
tiﬁcation converts proteomics in one of the most valuable
analytical resources to understand sophisticated cellular pro-
cesses at the functional level. However, if proteomics has to
deliver its resources and capabilities to the scientiﬁc com-
munity then, reliability, robustness and reproducibility must
be ensured. To this end, it is mandatory to deﬁne quality
control procedures and standardized protocols for the whole
proteomics workﬂow, from sample collection and preparation
to data computational analysis and exchange. Noteworthy,
the translation of analytical results into relevant biological
knowledge and practical applications is often hampered by
the lack of standardized protocols that emerge, which, there-
fore, is an urgent need. To this end the initiative will focus
on the standardization of proteomics workﬂows to consoli-
date a common space integrating proteomic strengths across
Europe, to increase the penetrance of proteomics in other sci-
entiﬁc disciplines, to facilitate the implementation of state
of the art methods and technology in emergent platforms
and, very importantly, to generate synergies with industrial
partners.
http://dx.doi.org/10.1016/j.euprot.2015.07.003
Afﬁnity Binder Knock-Down Initiative
Tove Alm ∗, Emma Lundberg, Mathias Uhlén
Royal Institute of Technology (KTH), SciLifeLab,
Stockholm, Sweden
Background: An enormous amount of publicly available
afﬁnity binders are available on the market and many of the
afﬁnity binders are not working as expected. Several studies
suggest that only 25–50% of the antibodies meet the expec-
tations. This results in a lot of wasted resources (material,
time, and money). Therefore, a quality assurance program in
proteomics research is needed.
Purpose: The purpose of the Afﬁnity Binder Knock-Down
Initiative (‘Initiative’) is to gather knowledge in a systematic
and standardized system to assure the functionality of afﬁnity
reagents.
Implementation: The research community and life science
companies will jointly work on improved quality of afﬁn-
ity reagents. The participating industrial partners provide
antibodies and gene silencing reagents and the researchers
use gene silencing to prove antibody speciﬁcity in partic-
ular application(s). The results are submitted back to the
Initiative and made publicly available on Antibodypedia
(www.antibodypedia.com, a site for searching and comparing
antibodies). The researchers are reimbursed for the positive
data submitted. By joining this public-private partnership, the
participating parts agree to fulﬁll a number of undertakings
that will be discussed during the presentation.
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The mission of the Initiative is to create a win–win con-
cept where we join forces to clean up the afﬁnity reagent
market.
http://dx.doi.org/10.1016/j.euprot.2015.07.004
Improving productivity and quality in
Biobanking: The need for synergy between
industry, academia, and the public sector
Åsa Wheelock
Karolinska Institutet, Stockholm, Sweden
The mission of the recently launched EuPA Biobank Ini-
tiative (www.eupa-biobank.eu) is to provide a forum and a
knowledge platform to the EuPA community regarding best
biobanking practices for a range of different applications and
situations, including both classical biobanking issues such
as standardized guidelines for successful in-house biobank-
ing or evaluation of sample stability and quality, as well as
more recently identiﬁed issues such as under-utilization of
biobank materials. These goals will be attained primarily by
acting as a link between the extensive experiences collected
by the EuPA community and the European and international
biobanking organizations, and ideally also to patient advocacy
groups and the biotech and pharma industry. The potential
beneﬁts of providing a forum and easy access to this type of
information to EuPA and the scientiﬁc community at large are
manifold, including improved quality of future sample collec-
tions and biobanks, improvedquality of the research produced
from these samples collections, as well as increased output
and productivity from existing biobanks. We are convinced
that, in order to reach extraordinary results, academia, indus-
try, and the public sector need to join forces. Through joint
efforts, we can contribute to moving biomedical proteomics
research beyond basic ﬁndings into clinical practice.
http://dx.doi.org/10.1016/j.euprot.2015.07.005
Independent validation initiative
Stefan Pellenz
Antibodies-online GmbH, Aachen, Germany
The reproducibility of scientiﬁc results is increasingly in the
spotlight within the scientiﬁc community and even beyond.
As one of the keystone reagents for proteomics research, anti-
bodies are of particular interest in this context. Commercially
available antibodies that do not perform according to expecta-
tion are putting a considerable load in ﬁnancial terms as well
as in terms of invested time on the end users.
As one of the leading online distributors of 1.5 mil-
lion proteomics products from more than 180 suppliers,
Antibodies-online is committed to provide high quality
reagents for the life sciences. To this endwehave launched the
Independent Validation with our partner Science Exchange to
provide reproducible validation data for selected applications
according to our customer’s requirements.
Since its inception in July 2013 more than 275 validations of
antibodies and ELISA kits have been carried out. In this time
window we have received almost 3000 validation requests
from our customers. This interest illustrates the need for a
program that offers relevant, independent, and standardized
validation data.
http://dx.doi.org/10.1016/j.euprot.2015.07.006
Novel product development and future
directions in support of proteomics
standardization, biobanking, and binder
validation using CRISPR knockout technology
Kevin Ray
Sigma-Aldrich Analytical R&D, St. Louis, MO,
USA
Sigma–Aldrich has a well-established history in the formu-
lation of analytical standards, including a portfolio of peptide
and protein standards for the development and evaluation of
proteomics workﬂows. We have participated in several inter-
laboratory studies with organizations such as the ABRF and
ProteoRed. Commercialization of associated reference mate-
rials allows the proteomics community to troubleshoot and
optimize sample preparation protocols and performance deﬁ-
ciencies of MS and LC systems. We are interested in further
activities aimed at standardization and QC to improve the
reproducibility of results within and across laboratories.
As a company Sigma–Aldrich is interested in providing
standards and kits which can be used to assess the integrity
of proteins and their PTMs within archived samples (serum,
plasma, and tissue) to ensure their suitability for use in future
analyses. Additionally, we are interested in developing afford-
able solutions for protein sample preservation and sample QC
tests which can be used to ensure the long-term integrity of
samples to be archived within biobanks.
We are also interested in exploring the utility of using
CRISPR knockout technology to validate Ab speciﬁcity. Val-
idating antibody speciﬁcity using knockdown technologies,
such as siRNA and shRNA, can be challenging for proteins
with low expression levels and/or long half-lives. Since CRISPR
technology is highly efﬁcient in creating speciﬁc and perma-
nent genetic knockout mutations, the treated cell population
should have signiﬁcantly more null cells compared to the
mock treated cell population.
Sigma–Aldrich anticipates this will allow more clear mea-
surement of differences between treated and untreated cells.
http://dx.doi.org/10.1016/j.euprot.2015.07.007
